#USA #Sarasota #biotherapeutics #Lakewood-Amedex #Nu-3

Positive Developments in Biopharmaceuticals

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT), a pioneering clinical-stage biotechnology company, has unveiled promising results for its leading antimicrobial candidate, Nu-3. This innovative drug is specifically designed for the treatment of mildly infected diabetic foot ulcers (iDFU), with the aim of addressing concerns surrounding antimicrobial resistance (AMR). As the company gears up for a Phase 2 clinical trial, their progress in developing and manufacturing the necessary components of this treatment is noteworthy.

The firm has successfully developed drug substances, the active ingredients, for several members of the Bisphosphocin® class—a new category of potent, fast-acting, broad-spectrum antimicrobials that aim to improve treatment efficacy against various infections. With efficient processes established in adherence to current Good Manufacturing Practices (cGMP), Lakewood-Amedex has made substantial advancements in both cost efficiency and the physical characteristics of the bulk drug substance.

Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, expressed confidence in their formulation and manufacturing processes, which have been optimized to produce high-quality Bisphosphocin® compounds. He highlighted Nu-3's unique mechanism that facilitates rapid microbial action, showcasing its potential against resilient infections. The company is enthusiastic about transitioning Nu-3 to the upcoming Phase 2 clinical trial, targeting specifically the treatment of iDFU.

Recent stability tests indicate that Nu-3 displays resilience over time, remaining stable for at least five years in its bulk drug form and two years as a finished product. The formulation's resistance to bioburden, which refers to the presence of viable microorganisms, is another promising aspect, as it has shown to maintain undetectable levels without the need for preservatives to sustain its antimicrobial properties.

In the laboratory, the Bisphosphocin® class has demonstrated an ability to swiftly eradicate bacteria by destabilizing their membranes, a mechanism that is essential in combatting antibiotic-resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE).

Focus on Nu-3 Development

Nu-3 stands out as Lakewood-Amedex's flagship product intended for topical application in treating iDFU. Drawing from the early exploratory clinical trials, the results have shown no safety concerns while also indicating a favorable antimicrobial response leading to enhanced wound healing. As part of their development strategy, the company plans to conduct a Phase 2a safety and dosage evaluation, followed by a placebo-controlled Phase 2b comparative study to determine the optimal dosing regimen for patients.

The progress made with Nu-3 reflects a broader commitment by Lakewood-Amedex to harness novel treatments that confront the growing issue of antimicrobial resistance. As they pave the way for new therapeutic options, there is a sense of urgency as well as optimism related to the forthcoming trials.

In summary, Lakewood-Amedex Biotherapeutics is poised to advance with Nu-3, marking a significant step forward in the field of biopharmaceuticals. With a robust grounding in science and an intuitive understanding of infectious diseases, the company is aiming to not only improve patient outcomes but also to mitigate the risks associated with antibiotic overuse. As more data gathers through clinical understanding, the hope is that Nu-3 will emerge as a crucial addition in the management of infected diabetic foot ulcers and potentially other serious infections.